Immunovia AB (publ) (IMMVF)
| Previous Close | 0.0000 |
| Open | 0.1500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1500 - 0.1500 |
| 52 Week Range | 0.0738 - 3.1550 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 12.528M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | Nov 27, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireImmunovia completes analytical validation of its next-generation pancreatic cancer test
Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set of parameters, reinforcing the reliability and robustness of the test.
PR NewswireChange in number of shares and votes in Immunovia AB (publ)
During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to underwriters in the rights issue resolved by the board of directors on 12 September 2024, based on the authorization granted by the annual general meeting on 19 June 2024. As of 30 September 2024, th
PR NewswireImmunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).
